Insight Molecular Diagnostics Inc. (IMDX)
| Market Cap | 135.11M |
| Revenue (ttm) | 4.05M |
| Net Income (ttm) | -50.22M |
| Shares Out | 32.17M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 342,341 |
| Open | 3.950 |
| Previous Close | 3.840 |
| Day's Range | 3.870 - 4.360 |
| 52-Week Range | 2.330 - 8.510 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+150.0%) |
| Earnings Date | May 13, 2026 |
About IMDX
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based tra... [Read more]
Financial Performance
In 2025, IMDX's revenue was $4.06 million, an increase of 115.58% compared to the previous year's $1.88 million. Losses were -$50.22 million, -17.57% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IMDX stock is "Strong Buy." The 12-month stock price target is $10.5, which is an increase of 150.00% from the latest price.
News
Insight Molecular Diagnostics Transcript: 25th Annual Needham Virtual Healthcare Conference
Insight Molecular Diagnostics is advancing GraftAssure, a decentralized transplant rejection test using droplet digital PCR, with strong clinical data and a dual quantification approach. The company targets rapid U.S. and EU expansion, robust margins, and is positioned to benefit from new anti-rejection therapies.
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland T...
Insight Molecular Diagnostics Earnings Call Transcript: Q4 2025
GraftAssureDx was submitted to the FDA, with commercialization and adoption efforts accelerating, supported by strong transplant center engagement and favorable clinical data. Financially, a $26M raise and robust sales pipeline position the company for growth, while market trends and reimbursement improvements provide additional tailwinds.
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quart...
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the mar...
Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score
NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potenti...
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health Sufficient clinical samples collected to support statistical analysis and FDA submiss...
iMDx Announces $26.0 Million Registered Direct Offering
NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with c...
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring
NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal...
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following invest...
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch
NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of V...
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion
NASHVILLE, Tenn., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today provided a year-end business update regarding its commercial progress, its GraftAs...
Insight Molecular Diagnostics Earnings Call Transcript: Q3 2025
Momentum is building toward a mid-2026 FDA submission and commercial launch, with strong clinical data, a robust cash position, and a $1B+ addressable market. Key risks include regulatory timelines and market adoption, but strategic investments and registry programs are driving engagement.
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch
On track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay's head-...
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the marke...
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
NASHVILLE, Tenn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it has welcomed Steven Tahmooressi to its executive leadership team...
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring
NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced results from a study conducted by iMDx researchers and partners publishe...
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced attendance at two key industry conferences where it will discuss its Gr...
Insight Molecular Diagnostics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Transplant monitoring is targeted as a $2B market with a decentralized, patent-protected test expected to launch by mid-next year, supported by strong clinical validation, top-tier partnerships, and high reimbursement. Early revenue may come from a new registry, with broader adoption driven by regulatory approval and clinical data.
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, Inc. (Nasdaq: IMDX), (“iMDx”), today announced a positive strategic update and novel registry that will serve to gat...
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it is actively enrolling patients in its clinical trial to assess Graf...
iMDx to Participate in NYC Investment Conferences September 8 - 11
NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright an...
Insight Molecular Diagnostics Transcript: KOL event
Decentralized cfDNA testing is poised to transform transplant care by enabling rapid, local detection of rejection, reducing unnecessary biopsies, and improving patient outcomes. Expanded payer support, workflow integration, and ongoing clinical validation are driving adoption and cost-effectiveness.
Insight Molecular Diagnostics Earnings Call Transcript: Q2 2025
Progress continues toward FDA submission and mid-2026 approval for Breptosure DX, with strong clinical trial engagement and assay improvements driving positive feedback. Q2 revenue and cash burn were in line with expectations, and commercial launch is targeted for next year.
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
Reiterating timelines for FDA submission in 2025 Transplant clinical trial has attracted leading transplant hospitals Booked first revenue from first-generation GraftAssureIQ research-use-only kits; b...